Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry
Authors' conclusion
In recipients with type 1 diabetes complicated by SHEs, islet transplantation meeting 4CFF protected 95% from SHEs at 5 years after the last islet infusion and exerted a large and significant benefit on glycaemic control, with an acceptable safety profile for this subgroup of type 1 diabetes.
Study context
- Population
- Non-uraemic islet transplant alone recipients with T1D and severe hypoglycaemic events, transplanted 1999–2015, ≥1 year follow-up
- Participants
- 398 recipients
- Exposure
- Recipients meeting four common favourable factors (4CFF) vs remaining recipients (<4CFF)
- 4CFFn = 126
- <4CFFn = 272reference
- Outcome
- Specified favourable outcomes:
- Freedom from SHEs
- HbA1c <53 mmol/mol (7.0%)
- Insulin independence
- Follow-up
- 5 years after the last islet infusion
Methodological detailsCollaborative Islet Transplant Registry
- Collaborative Islet Transplant Registry
Main finding
As reported in the abstract
Favourable outcomes in 4CFF recipients
4CFF: free of severe hypoglycaemic events (SHEs)
95%
4CFF: HbA1c <53 mmol/mol (7.0%)
76%
4CFF: HbA1c <53 mmol/mol (7.0%) and absence of SHEs
73%
4CFF: insulin independent
53%
Observational data: associations, not effects.
Safety
Per person
| Outcome | 4CFF | <4CFF |
|---|---|---|
| Procedural and immunosuppression-related SAEs resulting in sequelae, disability or death | 0.056 | 0.074 |
Original publication
Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry. Diabetologia. Published 6 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →